LAB

Standard BioTools Inc. Healthcare Medical Devices

9/12
Innovation Score

Patent Activity

2/3
10 patents found FUZZY

Cash Runway

3/3
60 months of cash remaining based on current burn rate.
Cash on hand: $455.2M

Revenue Trajectory

1/3
Revenue: $86.3M
YoY Growth: +4.6%

Management Quality

3/3
Insider ownership: 46.1%
SBC/Revenue: 0.0%
No reverse splits detected

Key Metrics

Market Cap $402.1M
Revenue $86.3M
Revenue Growth (YoY) +4.6%
Cash on Hand $455.2M
Cash Runway 60 months
Shares Outstanding 390.4M
Insider Ownership 46.1%
SBC / Revenue 0.0%
Sector / Industry Healthcare / Medical Devices

Patents (10)

Match type: FUZZY — company name matched partially; verify assignee

7-Step Risk Assessment

How LAB maps to our micro cap methodology:

  1. Innovation Signal 10 patents identified. This suggests the company is investing in defensible IP.
  2. Cash Runway Check 60 months of runway. Comfortable buffer for execution.
  3. Revenue Trajectory +4.6% YoY growth on $86.3M revenue. Positive but moderate growth.
  4. Management Alignment Insiders hold 46.1% of shares. SBC is 0.0% of revenue.
  5. Competitive Moat Review the company's 10-K for barriers to entry: patents, network effects, switching costs, regulatory approvals. This step requires manual research.
  6. Catalyst Identification Look for upcoming catalysts: FDA decisions, contract wins, product launches, partnerships. Check recent 8-K filings and earnings transcripts.
  7. Position Sizing Micro caps carry outsized risk. Consider position sizing relative to conviction level and portfolio concentration. This is a $402.1M company.

Financial Detail

Free Cash Flow $-13.4M
FCF Yield -3.3%
Return on Equity -9.9%
Debt / Equity 5.3%
Gross Margin 53.3%
Profit Margin 90.7%
Operating Margin -44.5%
Price / Book 0.72
Current Ratio 12.36
Dividend Yield None
Share Count Change (YoY) N/A
Share Count Change (3yr) N/A

Quality Flags

Low Debt

Free Cash Flow Trend

Insufficient Data
Consecutive Years FCF Positive 0

Disclaimer: This is an automated screening tool, not investment advice. Micro cap stocks are inherently risky with low liquidity and high volatility. The innovation score is based on publicly available data and may not reflect the full picture. Steps 5-7 of the methodology require your own research. See our full disclaimer.

Last screened: 2026-05-23